Cancer Patients May Be Treated With Drugs That Provide No Benefit
Many cancer patients may be treated with drugs that were granted accelerated approval but do not provide a clinical benefit, a study suggests.
Many cancer patients may be treated with drugs that were granted accelerated approval but do not provide a clinical benefit, a study suggests.
Adding pembrolizumab to frontline chemotherapy improves outcomes in patients with HER2-negative, advanced gastric or GEJ cancers, a phase 3 trial suggests.
The use of bariatric surgery in patients with severe obesity is associated with a reduced incidence of esophageal and gastric cancers.
Long-term results confirm that 4 courses of S-1 chemotherapy is inferior to the standard 8 courses in patients with stage II gastric cancer.
Patients with gastric cancer or dysplasia who underwent endoscopic submucosal dissection at very low-volume centers had a higher risk of adverse outcomes.
Combining regorafenib with best supportive care improves outcomes in advanced, refractory gastric/GEJ cancer, a phase 3 study suggests.
Tislelizumab plus chemotherapy may be a new first-line treatment option for patients with PD-L1-positive, advanced gastric or GEJ cancer.
Adding HER-Vaxx to standard chemotherapy improves survival in patients with HER2-overexpressing, advanced gastric or GEJ cancer, a study suggests.
Adding zolbetuximab to standard frontline chemotherapy can improve outcomes in certain patients with gastric/GEJ cancer, a phase 3 study suggests.
The COVID-19 pandemic delayed the diagnosis of gastric, esophageal, or GEJ cancer but did not impact survival in a single-center study.